Long-term immunogenicity of a single-dose live recombinant chimeric Japanese encephalitis vaccine in adults
Open Access
- 21 January 2025
- journal article
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 32 (2)
Abstract
Background: Japanese encephalitis virus is a leading cause of viral encephalitis in Asia, with high case-fatality rate and morbidity. Although the live recombinant Japanese encephalitis chimeric vaccine (Imojev®) offers strong initial immunity, data on long-term efficacy beyond 5 years remain limited. Methods: We conducted a cross-sectional study on adults vaccinated with Imojev® at a specialist travel clinic in Brisbane, Australia. Participants were stratified based on the time since vaccination: 2–5 years and >5 years. Neutralizing antibody titres were measured using the plaque reduction neutralization test (PRNT50), with titres ≥10 indicating seropositivity. Results: Of the 103 participants, 47 were vaccinated 2–5 years prior and 56 were vaccinated ≥5 years prior to enrolment. All participants vaccinated within 5 years remain seropositive, whilst 52 of 56 (92.9%) vaccinated ≥5 years ago were seropositive. Four participants (7.1%) were seronegative post-vaccination, with time since vaccination ranging from 5 to 9 years. These seronegative individuals were vaccinated a median of 9.2 years ago, compared to 5.1 years for seropositive participants (P-value = 0.037). Aside from time since vaccination, no other factors (e.g. age, sex) were associated with seronegativity. Conclusions: Imojev® provides durable immunity, with seropositivity exceeding 90% up to 10 years post-vaccination. However, waning immunity in a small proportion of individuals suggests that booster doses may be beneficial for high-risk travellers vaccinated over 5 years ago.Keywords
Funding Information
- Australian Infectious Disease Research Centre
- NHMRC Investigator (APP1193826)
- University of Queensland’s Amplify Initiative
This publication has 27 references indexed in Scilit:
- Characterisation of a Japanese Encephalitis virus genotype 4 isolate from the 2022 Australian outbreaknpj Viruses, 2024
- Persistence of antibodies, boostability, and interchangeability of Japanese encephalitis vaccines: A systematic review and dose-response meta-analysisVaccine, 2022
- Comparison of immunogenicity and safety of licensed Japanese encephalitis vaccines: A systematic review and network meta-analysisVaccine, 2021
- Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of diseaseHuman Vaccines & Immunotherapeutics, 2017
- Japanese encephalitis vaccineReactions Weekly, 2015
- Modelling the long-term persistence of neutralizing antibody in adults after one dose of live attenuated Japanese encephalitis chimeric virus vaccineVaccine, 2012
- Long term immunity following a booster dose of the inactivated Japanese Encephalitis vaccine IXIARO®, IC51Vaccine, 2011
- Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO®, IC51Vaccine, 2010
- Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2–3 September, 2004Vaccine, 2005
- Flavivirus EncephalitisNew England Journal of Medicine, 2004